Bioxytran (OTCMKTS: BIXT) is one of 897 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its competitors? We will compare Bioxytran to similar businesses based on the strength of its institutional ownership, valuation, profitability, earnings, analyst recommendations, dividends and risk.
Institutional & Insider Ownership
46.6% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 14.7% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Bioxytran has a beta of -5.86, meaning that its share price is 686% less volatile than the S&P 500. Comparatively, Bioxytran’s competitors have a beta of 1.08, meaning that their average share price is 8% more volatile than the S&P 500.
This table compares Bioxytran and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current ratings and target prices for Bioxytran and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Pharmaceutical preparations” companies have a potential upside of 77.03%. Given Bioxytran’s competitors higher probable upside, analysts plainly believe Bioxytran has less favorable growth aspects than its competitors.
Valuation & Earnings
This table compares Bioxytran and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Bioxytran Competitors||$1.70 billion||$121.98 million||-1.90|
Bioxytran’s competitors have higher revenue and earnings than Bioxytran. Bioxytran is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Bioxytran competitors beat Bioxytran on 7 of the 10 factors compared.
Bioxytran Company Profile
BioXyTran, Inc. engages in the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans, which is a lack of oxygen in tissues. Its product pipeline includes BXT-25, designed to oxygenate ischemic (reduced blood flow) regions in the brain that suffered from hypoxia during a brain stroke; and BXT-252, designed to treat chronic wounds resulting from ischemia caused by occlusion of capillaries. The company was founded on June 9, 2008 and is headquartered in Newton, MA.
Receive News & Ratings for Bioxytran Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioxytran and related companies with MarketBeat.com's FREE daily email newsletter.